Printer Friendly

THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT

 THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
 ATLANTA, Aug. 3 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX), an Atlanta-based cancer therapy company, today announced that, for the second quarter ended June 30, 1992, the company recorded a net profit of $374,000, or 3 cents per share, compared to a net profit of $47,000, or $.00 per share, for the same period last year.
 Theragenics' revenue for the second quarter of fiscal 1992 was $1,158,000, a 121 percent improvement on the $525,000 in revenues recorded for the second quarter of 1991.
 For the six months of fiscal 1992, the company recorded a net profit of $880,000, or 8 cents per share, a 138 percent improvement on the net profit of $369,000, or 4 cents per share, recorded for he first half of fiscal 1991. Theragenics' revenue of the first two quarters of fiscal 1992 was $2,362,000, compared to revenue of $1,309,000 recorded for the same period last year.
 Chairman and CEO, John V. Herndon attributed Theragenics' revenue and profit growth over the previous year to a "considerable increase" in the demand for the company's TheraSeed(R) product, a nonsurgical, outpatient treatment which is used to eradicate prostate cancer. Herndon added, however, that as original plans for 1992 called for quarterly growth rates of between 50 to 100 percent over the previous year, growth rates in excess of 100 percent, such as achieved in the second quarter of 1992, could potentially create a lag in meeting customer demand for TheraSeed. Therefore, said the CEO, third and fourth quarter growth rates will adhere more closely to our original goal of 50 to 100 percent.
 TheraSeed, although used predominately in the treatment of prostate cancer, has also been used to treat cancers of the lung, pancreas, head and neck, brain and vagina.
 THERAGENICS CORPORATION
 (Unaudited -- in thousands, except per share data)
 Periods ended Three months Six months
 June 30 1992 1991 1992 1991
 Revenues $1,158 $525 $2,362 $1,309
 Earnings 374 47 $880 $369
 Earnings per share $0.03 $.00 $0.08 $0.04
 Weighted average
 number of shares 11,119,215 9,873,747 11,129,518 9,866,710
 -0- 8/3/92
 /CONTACT: Bruce Smith, CFO of Theragenics, 404-381-8338, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/
 (THRX) CO: Theragenics Corp. ST: Georgia IN: MTC SU: ERN


SH-TS -- NY009 -- 5995 08/03/92 09:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1992
Words:416
Previous Article:STORAGETEK SIGNS MULTI-MILLION DOLLAR AGREEMENT WITH AT&T
Next Article:SOCIETY CORPORATION TO LIST ON THE NEW YORK STOCK EXCHANGE
Topics:


Related Articles
BELLINGHAM INDUSTRIES ACQUIRES 24.1 PERCENT OF THERAGENICS
THERAGENICS RECORDS RECORD FOURTH QUARTER AND YEAR END RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 227 PERCENT
THERAGENICS RAISES $3 MILLION IN PRIVATE PLACEMENT
HENLEY INTERNATIONAL REPORTS RECORD SECOND QUARTER AND SIX MONTH RESULTS
THERAGENICS NAMES CHRISTINE JACOBS PRESIDENT AND C.O.O.
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY PROFITS INCREASE NEARLY THREE-FOLD; REVENUES ALSO SOAR
THERAGENICS ANNOUNCES 1992 RESULTS; SALES INCREASE 58 PERCENT AND PROFITS DOUBLE; 1993 FORECAST SHOWS PROFITS UP 167 PERCENT
THERAGENICS ANNOUNCES 1993 RESULTS
Vysis Reports Solid First Quarter 2001 Financial Performance.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters